Group

🦠 Human Respiratory Syncytial Virus (RSV)

Treatment: Overview

Respiratory Syncytial Virus (RSV) is a common viral infection that primarily affects the lungs and respiratory tract, especially in infants, young children, older adults, and immunocompromised individuals.

🔍 What Is RSV?

• A highly contagious virus causing cold-like symptoms, bronchiolitis, or pneumonia

• Most common in babies under 2 years old

• Seasonal outbreaks occur typically in fall through early spring

• 
  

💊 Current Treatment Options

There is no specific antiviral cure for RSV, but treatments aim to relieve symptoms and prevent complications:

1. Supportive Care

• Hydration

• Oxygen therapy (for severe cases)

• Nasal suctioning to clear airways

2. Antiviral Therapies

• Ribavirin (rarely used, reserved for severe cases)

3. Monoclonal Antibodies

• Palivizumab (Synagis): Preventive for high-risk infants (monthly injections during RSV season)

• Nirsevimab (Beyfortus): A new, long-acting preventive option with a single-dose strategy for infants

4. Vaccines

• RSV vaccines for older adults and pregnant women now approved (e.g., Arexvy by GSK, Abrysvo by Pfizer)

• Goal: protect infants through maternal antibodies and adults from severe illness

📈 Market Outlook

• RSV therapeutics and prophylactics market is growing fast

• Global RSV treatment market size (2024): ~$2.8–3.2 billion

• Expected CAGR (2024–2032): ~9–12%

• Driven by:

• Increased awareness

• Vaccine approvals

• Rising RSV-related hospitalizations in aging populations

🏥 Key Players

• Sanofi & AstraZeneca (Nirsevimab)

• GSK (Arexvy vaccine)

• Pfizer (Abrysvo vaccine)

• Moderna (RSV mRNA vaccine in development)

• SAB Biotherapeutics, Meissa Vaccines, Novavax (in trials)